Pharma intelligence in minutes,
not meetings.

FDA approvals, trials, patents, pipelines — into clear decisions, fast.

Try: · · · · ·

8,600+ drugs · 154,000+ trials · 1,300+ patent landscapes · Updated weekly.

Start 30-day Pro trial — free → No credit card required

What is TheraRadar?

TheraRadar is a reference on prescription drugs and the companies that develop them, built from public records. For each of its 8,600+ FDA-approved drugs it shows the approvals and, where they exist, the label, the patents and the clinical trials that test the drug. It follows the FDA's upcoming decision dates (PDUFA dates) and its new approvals, maps who is developing drugs in each mechanism class in its mechanism heatmaps, and explains the science and the business behind the drugs in plain-English briefs.

The data comes from the FDA (Drugs@FDA, drug labels, the Orange Book and the Purple Book), ClinicalTrials.gov, and companies' SEC filings and results reports, and is refreshed every week.

Questions TheraRadar answers

Tap any question to jump straight to the data.

When does Keytruda's patent expire? Who's developing GLP-1 drugs? What FDA decisions are coming? How big is Humira's global patent portfolio? What Phase 3 readouts are expected? How crowded is the Alzheimer's space? Which companies are developing NSCLC drugs? What drugs were approved this year?

Recent FDA Approvals

Updated Nov 8, 2026

AVYXA HOLDINGS, LLC.

XBRANE BIOPHARMA AB

Upcoming FDA Decisions

Ivonescimab + chemotherapy

Summit Therapeutics Inc.

November 14, 2026

0d away

IGALMI

BioXcel Therapeutics, Inc.

November 14, 2026

0d away

MYQORZO (aficamten)

Cytokinetics, Incorporated

November 14, 2026

0d away

From the briefs

Plain-English deep dives on the science and strategy behind the drugs.

Can IL-23 Drugs for Crohn's Start at Home? Some Crohn's drugs already start with injections or a pill, but most IL-23 drugs still begin with clinic or hospital infusions. AbbVie wants to change that for Skyrizi, after its AFFIRM trial showed that starting with injections works. 5 min read Approved Early, Proven Later? What Happens to Cancer Accelerated Approvals The FDA can put a cancer drug on the market years early, on the promise that proof will follow. We checked all 219 oncology accelerated approvals on the FDA's own lists to see how often a drug with accelerated approval goes on to get full approval. 9 min read How to Read a Cancer Trial and Tell If Patients Live Longer A cancer drug 'works.' But did patients live longer, or did a tumor just shrink? The answer is which endpoint the trial made its primary measure. Here is how to read it. 8 min read The Daraxonrasib Success Story How RAS went from "undruggable" to Rasonque, the first RAS-targeted medicine to extend survival in pancreatic cancer, and the best reporting and science behind it. 6 min read Can an IBD Biologic Last Six Months? Several companies want to stretch IBD antibodies from a shot every few weeks to one every three months, or even six. Keeping the drug in the blood that long is the easy part. Whether the disease stays controlled right up to the next dose is the hard part, and the bet the newest programs are making. 8 min read Does Blocking IL-17F Actually Matter? Two of the newest PsA drugs block IL-17F as well as IL-17A; the older ones block only IL-17A. A plain walk through what the extra target actually buys: clear help on the skin, no proven help on the joints yet, and a fungal cost in the middle. 10 min read

Pro tools

Pre-built analyses. The slow research is already done.

View all dashboards →

Competitive heatmaps

90+ interactive grids — indication landscapes (company × mechanism), company portfolios, and MOA platforms. Click any cell to drill into the trials.

Compare two companies

Head-to-head comparison of any two company portfolios — pipeline, approvals, and revenue side by side.

Clinical Trials Explorer

Search and filter 154,000+ trials by drug, sponsor, phase, and condition.

Patent Cliff with revenue arcs

Humira -73%, Revlimid -81%, Stelara -43% — actual SEC revenue declines, not Medicare proxies.

Or skip the work entirely — read the report

Crohn's Disease Landscape 2026

TNF, IL-23, JAK, TL1A mechanism breakdown.

Ulcerative Colitis Landscape 2026

S1P modulators, biologics, pipeline.

Alzheimer's Disease Landscape 2026

Anti-amyloid therapies, pipeline gaps.

Data sources: FDA Drugs@FDA, ClinicalTrials.gov, Orange Book, SEC EDGAR.

Data updated: Nov 12, 2026